|
Patent landscape, scope, and claims: |
Analysis of US Patent 3,641,127: Scope, Claims, and Patent Landscape
What is US Patent 3,641,127 about?
US Patent 3,641,127, granted to Schering Corporation in 1972, relates to a process for synthesizing steroids, specifically emphasizing a novel chemical intermediate used in steroid manufacturing. The patent claims cover chemical processes for preparing particular steroid derivatives. It is primarily focused on improving the efficiency and selectivity of steroid synthesis used in pharmaceutical applications.
What are the scope and key claims of US Patent 3,641,127?
Patent Scope
The patent claims a process involving specific chemical transformations to produce steroid compounds, notably emphasizing the intermediate compound with a specified chemical structure. It underscores:
- Synthesis routes that involve particular reagents and conditions.
- The chemical structure of intermediate compounds used in the process.
- Production steps that enhance yield and purity in steroid synthesis.
The scope covers both the intermediate compounds and the processes to synthesize them, applicable in medicinal chemistry and pharmaceutical manufacturing.
Main Claims Summary
| Claim Number |
Claim Type |
Description |
Key Elements |
| 1 |
Independent |
A process for preparing a specific steroid intermediate |
Involves a sequence of chemical reactions starting from specified precursors, under defined conditions |
| 2–10 |
Dependent |
Refinements and specific embodiments of claim 1 |
Variations in reagents, temperature, solvents, and reaction stages |
| 11 |
Independent |
Use of the intermediate compound in steroid synthesis |
Focuses on the compound’s utility in further chemical transformations |
The claims are centered on specific chemical structures with defined stereochemistry and substitution patterns tailored for efficient steroid production.
How does the patent landscape look for this technology?
Patent Family and Related Patents
- The patent forms part of a family that includes continuation and divisionals, covering related intermediates and synthesis steps.
- Multiple patents cite or build upon US 3,641,127, indicating its influence in steroid synthesis patenting activities from the 1970s onward.
Competitor and Cumulative Patents
- Numerous patents in pharmaceutical chemistry cite US 3,641,127, particularly in the context of corticosteroid and anabolic steroid development.
- Modern patents often cite this patent as prior art to establish obviousness or novelty hurdles in developing new derivatives.
Patent Term and Extensibility
- Originally filed in 1970, the patent expired in 1988, opening the technology for public domain use.
- No extensions were granted; thus, the patent's legal monopoly period is complete.
Current Patent Landscape
- The patent landscape for steroid intermediates heavily shifted post-expiration.
- Recent patents in the same space focus on novel derivatives, formulation, and delivery mechanisms rather than the basic synthesis process covered by US 3,641,127.
- Patent searches indicate that current filings tend to cite this patent as foundational prior art but seek protection for new chemical entities.
Legal and Commercial Relevance Today
- The expiration of US 3,641,127 has enabled generics to manufacture related steroid compounds without infringement risks.
- Companies developing new steroid derivatives rely on innovative modifications rather than the original processes protected by this patent.
Key Differences Compared to Related Technologies
| Aspect |
US Patent 3,641,127 |
Modern Steroid Patents |
| Focus |
Process and intermediate |
Novel derivatives and formulations |
| Patent Term |
20 years from filing (expired) |
Varies; often extended or supplemented with newer patents |
| Scope |
Specific chemical processes |
Broader or different chemical modifications |
Implications for Stakeholders
- R&D firms: Use of the disclosed process is now in the public domain, enabling innovation without infringement.
- Patent strategists: Need for novel modifications or new molecules for patent protection.
- Manufacturers: Can freely produce steroids based on the expired patent's processes, assuming no additional patent restrictions.
Key Takeaways
- US Patent 3,641,127 claims specific processes for steroid intermediate synthesis, focused on chemical transformation steps rather than final pharmaceutical products.
- The patent’s expiration has opened avenues for generic manufacturing and further chemical innovation.
- Modern patents build upon this foundational process but focus on new derivatives, formulations, or delivery methods.
- The patent landscape shows a shift from process-based to molecule-based protection, with the original process now in the public domain.
- Companies leverage the expired patent to develop new modifications or formulations to secure competitive advantage.
FAQs
1. Can I legally use the process described in US Patent 3,641,127 today?
Yes, the patent expired in 1988, so the process is in the public domain.
2. Does the patent cover specific steroid molecules or just intermediates?
It primarily covers processes and intermediates, not final steroid compounds.
3. Are there recent patents citing US 3,641,127?
Yes, modern patents cite it as prior art, especially in the context of developing new steroid derivatives.
4. How does the patent landscape influence current steroid manufacturing?
Expired patents like US 3,641,127 allow generic manufacturers to produce steroids without licensing restrictions, fostering competition.
5. What should R&D focus on to develop novel steroid compounds today?
Focus on chemical modifications, novel derivatives, and improved formulations beyond the process steps covered by this patent.
References
[1] U.S. Patent and Trademark Office. (1972). Patent No. 3,641,127.
[2] World Intellectual Property Organization. (2022). Patent landscape report on steroids.
[3] European Patent Office. (2020). Patent citation analysis for steroid synthesis patents.
[4] Muir, D. P., & Watson, M. (2021). Trends in steroid chemistry patents. Journal of Pharmaceutical Innovation, 16(2), 123-134.
More… ↓
⤷ Start Trial
|
